Healthcare

Vitrafy Life Sciences (ASX:VFY) is in focus as the cryopreservation hopeful has quadrupled off its lows, but a maiden full-year result — a $16.2 million loss on $209,000 of revenue — has put a spotlight on a valuation the market is straining to justify.

Trajan Group (ASX:TRJ) is approaching its FY26 results with investors focused on whether the analytical science company can improve profitability, strengthen cash generation, and manage its balance sheet following a difficult period.

Artrya (ASX:AYA) is transitioning from a regulatory-driven healthcare technology story into a commercialisation phase, with investors assessing whether its Salix platform can generate scalable revenue from US healthcare customers.

Singular Health Group is a Perth-based medical imaging software company focused on developing technology for viewing and manipulating medical images. Its flagship 3Dicom platform is designed to render CT and MRI scans in two and three dimensions for clinicians and patients. The company’s product …

INOVIQ (ASX:IIQ) is entering a critical stage after its EXO-OC ovarian cancer diagnostic validation program was disrupted by issues with archived international biobank samples.

The company's own market-moving event is still ahead. Telix is scheduled to release its half-year results for the six months to 30 June 2026 on Thursday 20 August, two trading days after Tuesday's rally.

There was no obvious company-specific shock behind the move. ResMed did not release a new price-sensitive announcement on the day, there was no disclosed downgrade to guidance and no fresh regulatory setback.